Erenumab for Idiosyncratic Facial Pain

  • STATUS
    Recruiting
  • End date
    Feb 10, 2024
  • participants needed
    66
  • sponsor
    David Jang, M.D.
Updated on 10 July 2022
edema

Summary

This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or radiographic evidence of sinusitis.

Description

Eligible participants are randomized to receive either Erenumab or placebo by subcutaneous injection once monthly for 6 months. Study duration is eight months which includes a 30 day screening/lead-in period and 6 monthly treatment visits followed by a follow-up visit one month following the last dose of study drug administration. Participants will be expected to score on a scale of 1 to 10 their symptoms of facial pain/pressure, nasal congestion, and rhinorrhea as well well as any rescue medicines taken for pain each day via a mobile app.

Details
Condition Facial Pain, Rhinosinusitis
Treatment Placebo, Erenumab Prefilled Syringe
Clinical Study IdentifierNCT04249427
SponsorDavid Jang, M.D.
Last Modified on10 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Adults 18 years of age and older presenting to Duke Head & Neck Surgery and Communications Sciences clinic for evaluation of rhinosinusitis and/or facial pain or pressure
Symptoms are present at least 10 days a month for the last 3 months as reported by subject
Symptoms must include midfacial pain or uncomfortable pressure (may be unilateral or bilateral), which is defined as pain in the regions overlying the maxillary, ethmoid, frontal sinuses either together or individually
Nasal endoscopy in the last three months shows no signs of inflammation (i.e. thick drainage, polyps, watery edema in the middle meatus or spheno-ethmoid recess (mild edema permitted)
Sinus CT scan or MRI within 12 months of enrollment during a symptomatic period shows no more than scattered minimal mucosal edema or mucous retention cyst with patent infundibula bilaterally. For subjects with a CT scan more than 12 months old or just an MRI, a CT will be repeated for study purposes. For patients with CT scans less than 12 months old, a CT will be repeated for study purposes if the subject has changes in symptoms suggestive of sinusitis
Ability to read/write English
Has a smart phone, ipod or iPad touch for completion of the EMA on a daily basis

Exclusion Criteria

Previous exposure to erenumab or any other CGRP inhibitor in the six months prior to treatment
Hypersensitivity to erenumab or to any of the drug components (acetate, polysorbate, and sucrose)
Allergy to latex
On a preventative migraine medication (see below) during the 30 day lead-in period
Inability to differentiate facial pain from other headaches
Non-English speaking or unable to provide written informed consent
Category 1: Divalproex sodium, sodium valproate
Category 2: Topiramate
Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, nadolol, ebivolol, pindolol, propranolol, timolol)
Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline, protriptyline)
Category 5: Serotonin-norepinephrine reuptake inhibitors (for example: venlafaxine, desvenlafaxine, duloxetine, milnacipran)
Received botulinum toxin (Botox) to the head and neck for migraines in the last four
Category 6: Flunarizine, verapamil
months
Category 7: Lisinopril, candesartan
More than one major open surgery of the nose or sinuses for sinonasal cancer
Active seizure disorder or other significant neurological conditions other than migraine
History of metastatic malignancy in the last five years or actively undergoing treatment for cancer
History of liver failure
Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina, or coronary artery bypass surgery or other revascularization procedure within 12 months prior to screening
History or evidence of any other unstable or clinically significant medical condition that in the opinion of the sponsor-investigator/ Principal Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
Evidence of drug or alcohol abuse or dependence within 12 months prior to screening, based on medical records or patient self-report
Age ≥ 55 years with cessation of menses for 12 or more months, OR
Pregnant or breastfeeding, or expecting to conceive during the study, including through 16 weeks after the last dose of investigational product or placebo
Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during treatment with investigational product or placebo through 16 weeks after the last dose of investigational product. Female subjects not of childbearing potential are defined as any female who is post-menopausal by history, defined as
Age < 55 years but no spontaneous menses for at least 2 years, OR
Underwent bilateral oophorectomy, bilateral salpingectomy, or hysterectomy
Unlikely to be able to complete all protocol required study visits or procedures
Currently receiving treatment in another investigational device or drug study
History of uncontrolled or unstable blood pressure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note